Ophthotech Raises $36 million, In-licenses Aptamers

Three venture capital firms funded the ophthalmology start-up with a $36 million Series A that will pay for the acquisition of two IND-stage drug candidates: the similarity to another start-up, Lux Biosciences, is startling. Can the founders of Eyetech take the Lux model and build another success for SVLS, HBM Bioventures, and Novo AS?